Cited by 225Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

Tsimikas, Sotirios, Witztum, Joseph L., Miller, Elizabeth R., Sasiela, William J., Szarek, Michael, Olsson, Anders G., Schwartz, Gregory G.·2004·Circulation

DOI 10.1161/01.cir.0000141728.23033.b5

Open this paper in CoChat — free account

Abstract

Background— Oxidized phospholipids (OxPL) are present within atherosclerotic plaques and bound by lipoprotein (a) [Lp(a)] in plasma. This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS). Methods and Results— OxLDL-E06 (OxPL content on apolipoprotein B-100 [apoB] detected by antibody E06), apoB-100 immune complexes (apoB-IC), OxLDL autoantibodies, and Lp(a) levels were measured in 2341 patients at baseline and after 16 weeks of treatment with atorvastatin 80 mg/d or placebo. The OxLDL-E06 and apoB-IC data are reported per apoB-100 particle (OxPL/apoB, IC/apoB) and as total levels on all apoB-100 particles (total apoB-OxPL and total apoB-IC [eg, OxPL/apoB or IC/apoB×apoB-100 levels]). Compared with baseline values, atorvastatin reduced apoB-100 (−33%), total apoB-OxPL (−29.7%), total apoB-IC IgG (−29.5%), and IgM (−25.7%) ( P <0.0001 for all), whereas no change or an increase was observed with placebo. When normalized per apoB-100, compared with placebo, atorvastatin increased OxPL/apoB (9.5% versus −3.9%, P <0.0001) and Lp(a) (8.8% versus −0.7%, ( P <0.0001). A strong correlation was noted between OxPL/apoB and Lp(a) ( R =0.85, P <0.0001), consistent with previous data that Lp(a) binds OxPL. Conclusions— After atorvastatin treatment, total OxPL on all apoB-100 particles was decreased. However, there was enrichment of OxPL on a smaller pool of apoB-100 particles, in parallel with similar increases in Lp(a), suggesting binding by Lp(a). These data support the hypothesis that atorvastatin promotes mobilization and clearance of proinflammatory OxPL, which may contribute to a reduction in ischemic events after ACS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000141728.23033.b5

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citation
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,274
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques
Crisby, M., Fredrikson, G. N., Shah, P. K., Yano, J., Zhu, J., & Nilsson, J. Å. (2001) · Circulation · doi:10.1161/01.cir.103.7.926 · Cited by 999
Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes
Ehara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 780
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL
Binder, C. J., Hörkkö, S., Dewan, A. K., Chang, M.-K., Kieu, E., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., & Silverman, G. J. (2003) · Nature Medicine · doi:10.1038/nm876 · Cited by 735
Self-citation

Show all 45 references

Research works printed but not linked: 10

1994, Lancet, 344, 1383
10.1161/circ.97.24.2433 · DOI
10.1161/atvb.21.11.1712 · DOI
2003, J Cardiovasc Risk, 10, 181
10.1161/circ.103.15.1955 · DOI
10.1161/circ.95.1.76 · DOI
10.1161/atvb.20.3.689 · DOI
10.1161/circ.103.7.926 · DOI
10.1161/hyp.33.1.53 · DOI
10.1161/atvb.21.1.101 · DOI

Sorted by citations

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043175 · Cited by 782
Self-citation
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Self-citation
Statin therapy increases lipoprotein(a) levels
Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz310 · Cited by 512
Self-citation
Role of Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis
Zalewski, A. A., & Macphee, C. H. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000160551.21962.a7 · Cited by 476
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma
Bergmark, C., Dewan, A. K., Orsoni, A., Merki, E., Miller, E. R., Shin, M., Binder, C. J., Hörkkö, S., Krauss, R. M., Chapman, M. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800174-jlr200 · Cited by 410
Self-citation
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H. E., Blom, D. J., Eriksson, M., Dent, R. E., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 365
C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.066 · Cited by 332
Self-citation
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
Trpković, A., Resanović, I., Stanimirović, J., Radak, D. J., Mousa, S. A., Cenic-Milosevic, D., Jevremović, D., & Isenović, E. R. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.992063 · Cited by 326
The role of B cells in atherosclerosis
Sage, A. P., Tsiantoulas, D., Binder, C. J., & Mallat, Z. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0106-9 · Cited by 298
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0153-2 · Cited by 298
Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy
Kini, A. S., Baber, U., Kovacic, J. C., Limaye, A. M., Ali, Z. A., Sweeny, J. M., Maehara, A., Mehran, R., Dangas, G., Mintz, G. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.058 · Cited by 283
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events
Tsimikas, S., Brilakis, E. S., Lennon, R. J., Miller, E. R., Witztum, J. L., McConnell, J. P., Kornman, K. S., & Berger, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600361-jlr200 · Cited by 260
Self-citation
Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes
Kiechl, S. J., Willeit, J., Mayr, M., Viehweider, B., Oberhollenzer, M., Kronenberg, F., Wiedermann, C. J., Oberthaler, S., Xu, Q., Witztum, J. L., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.145805 · Cited by 249
Self-citation
Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events
Tsimikas, S., Willeit, P., Willeit, J., Santer, P., Mayr, M., Xu, Q., Mayr, A., Witztum, J. L., & Kiechl, S. J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.979 · Cited by 219
Self-citation
Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – Novel insights and future directions in diagnosis and therapy,
Hartley, A., Haskard, D. O., & Khamis, R. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.05.010 · Cited by 219
Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia
Santos, R. D., Raal, F. J., Catapano, A. L., Witztum, J. L., Steinhagen‐Thiessen, E., & Tsimikas, S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304549 · Cited by 197
Self-citation
Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease
Tsimikas, S., Kiechl, S. J., Willeit, J., Mayr, M., Miller, E. R., Kronenberg, F., Xu, Q., Bergmark, C., Weger, S., Oberhollenzer, F., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.001 · Cited by 196
Self-citation
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
OLSSON, A. G., Schwartz, G. G., Szarek, M. J., Sasiela, W. J., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D. D., & Zeiher, A. M. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi186 · Cited by 193
Self-citation
Oxidized Phospholipids on apoB-100-Containing Lipoproteins: a Biomarker Predicting Cardiovascular Disease and Cardiovascular Events
Taleb, A., Witztum, J. L., & Tsimikas, S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.60 · Cited by 186
Self-citation
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis
de Boer, L. M., Oorthuys, A. O. J., Wiegman, A., Langendam, M. W., Kroon, J., Spijker, R., Zwinderman, A. H., & Hutten, B. A. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab171 · Cited by 189
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy
Desai, N. R., Kohli, P., Giugliano, R. P., O’Donoghue, M. L., Somaratne, R. M., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001969 · Cited by 179
Pleiotropic effects of statins: new therapeutic targets in drug design
Bedi, O., Dhawan, V., Sharma, P. L., & Kumar, P. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1252-4 · Cited by 186
Monocyte tissue factor–dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin
Owens, A. P., Passam, F. H., Antoniak, S., Marshall, S., McDaniel, A. L., Rudel, L. L., Williams, J., Hubbard, B. K., Dutton, J., Wang, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58969 · Cited by 171
Circulating oxidized LDL: a biomarker and a pathogenic factor
Ishigaki, Y., Oka, Y., & Katagiri, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832fa58d · Cited by 162
Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice
Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation · doi:10.1161/circulationaha.108.786822 · Cited by 156
Self-citation
Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease
Fraley, A. E., & Tsimikas, S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000245255.40634.b5 · Cited by 153
Self-citation
Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events
Tsimikas, S., Mallat, Z., Talmud, P. J., Kastelein, J. J. P., Wareham, N. J., Sandhu, M. S., Miller, E. R., Bénessiano, J., Tedgui, A., Witztum, J. L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.048 · Cited by 152
Self-citation
New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis and Cardiovascular Disease
Tsimikas, S., Tsironis, L. D., & Tselepis, A. D. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000280571.28102.d4 · Cited by 152
Self-citation
Untitled work
Yeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Self-citation
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors
Tsimikas, S., Clopton, P., Brilakis, E. S., Marcovina, S. M., Khera, A., Miller, E. R., de Lemos, J. A., & Witztum, J. L. (2009) · Circulation · doi:10.1161/circulationaha.108.836940 · Cited by 151
Self-citation
Oxidized phospholipids in cardiovascular disease
Tsimikas, S., & Witztum, J. L. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00937-4 · Cited by 166
Self-citation
Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic Actions
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.008 · Cited by 153
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function
Watson, C. E., Weissbach, N., Kjems, L., Ayalasomayajula, S. P., Zhang, Y., Chang, I., Navab, M., Hama, S. Y., Hough, G., Reddy, S. T., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011098 · Cited by 152
Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial
Budoff, M. J., Ahmadi, N., Gul, K. M., Liu, S. T., Flores, F. R., Tiano, J., Takasu, J., Miller, E. R., & Tsimikas, S. (2009) · Preventive Medicine · doi:10.1016/j.ypmed.2009.06.018 · Cited by 147
Self-citation
Measurement of Plasma Oxidized Low-Density Lipoprotein and its Clinical Implications
Itabe, H., & Ueda, M. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.1 · Cited by 147
Oxidative Modification of LDL: Its Pathological Role in Atherosclerosis
Itabe, H. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8095-9 · Cited by 146
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
Tsimikas, S., & Witztum, J. L. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328308b622 · Cited by 138
Self-citation
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study
Ravandi, A., Boekholdt, S. M., Mallat, Z., Talmud, P. J., Kastelein, J. J. P., Wareham, N. J., Miller, E. R., Bénessiano, J., Tedgui, A., Witztum, J. L., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m015776 · Cited by 136
Self-citation
The Dynamics of Oxidized LDL during Atherogenesis
Itabe, H., Obama, T., & Kato, R. (2011) · Journal of Lipids · doi:10.1155/2011/418313 · Cited by 128
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
Gilliland, T., Liu, Y., Mohebi, R., Miksenas, H., Haidermota, S., Wong, M., Hu, X., Cristino, J., Browne, A., Plutzky, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.050 · Cited by 110
Self-citation
The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans
Ky, B., Burke, A., Tsimikas, S., Wolfe, M. L., Tadesse, M. G., Szapary, P. O., Witztum, J. L., FitzGerald, G. A., & Rader, D. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.026 · Cited by 124
Self-citation
Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance
Harmon, D. B., Srikakulapu, P., Kaplan, J. L., Oldham, S. N., McSkimming, C. C., Garmey, J. C., Perry, H. M., Kirby, J. L., Prohaska, T. A., Gonen, A., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307166 · Cited by 126
Self-citation
Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes
Fraley, A. E., Schwartz, G. G., OLSSON, A. G., Kinlay, S., Szarek, M. J., Rifai, N., Libby, P., Ganz, P., Witztum, J. L., & Tsimikas, S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.041 · Cited by 113
Self-citation
Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)
Yeang, C., Hung, M., Byun, Y. S., Clopton, P., Yang, X., Witztum, J. L., & Tsimikas, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.005 · Cited by 110
Self-citation
Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis
Papac-Miličević, N., Busch, C. J., & Binder, C. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.02.001 · Cited by 112
Oxidative Biomarkers in the Diagnosis and Prognosis of Cardiovascular Disease
Tsimikas, S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.015 · Cited by 111
Self-citation
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“Studies reported no or only a minor increase in lipoprotein (a) (Lp(a)) levels among patients treated with statins [33, 34].”
Background
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
Inflammatory Biomarkers in Acute Coronary Syndromes
Armstrong, E. J., Morrow, D. A., & Sabatine, M. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595538 · Cited by 103
Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease
Bertoia, M. L., Pai, J. K., Lee, J. H., Taleb, A., Joosten, M. M., Mittleman, M. A., Yang, X., Witztum, J. L., Rimm, E. B., Tsimikas, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.047 · Cited by 97
Self-citation
Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume
Choi, S., Chae, A., Miller, E. R., Messig, M., Ntanios, F. Y., DeMaria, A. N., Nissen, S. E., Witztum, J. L., & Tsimikas, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.066 · Cited by 99
Self-citation
Tea Catechin Consumption Reduces Circulating Oxidized Low-Density Lipoprotein
Inami, S., Takano, M., Yamamoto, M., Murakami, D., Tajika, K., Yodogawa, K., Yokoyama, S., Ohno, N., Ohba, T., Sano, J., et al. (2007) · International Heart Journal · doi:10.1536/ihj.48.725 · Cited by 95
Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings
Rodenburg, J., Vissers, M. N., Wiegman, A., Miller, E. R., Ridker, P. M., Witztum, J. L., Kastelein, J. J. P., & Tsimikas, S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.047 · Cited by 92
Self-citation
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology
Koschinsky, M. L., & Boffa, M. B. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.001 · Cited by 94
Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet
Faghihnia, N., Tsimikas, S., Miller, E. R., Witztum, J. L., & Krauss, R. M. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005769 · Cited by 90
Self-citation
Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients
Moriarty, P. M., Varvel, S. A., Gordts, P. L. S. M., McConnell, J. P., & Tsimikas, S. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308704 · Cited by 89
Self-citation
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis
Yeang, C., Wilkinson, M. J., & Tsimikas, S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000300 · Cited by 89
Self-citation
Oxidized low-density lipoprotein biomarkers in atherosclerosis
Tsimikas, S. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0065-1 · Cited by 88
Self-citation
Granulocyte Macrophage Colony-Stimulating Factor Regulates Dendritic Cell Content of Atherosclerotic Lesions
Shaposhnik, Z., Wang, X., Weinstein, M. M., Bennett, B. J., & Lusis, A. J. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000254673.55431.e6 · Cited by 87
Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: Reduction during atorvastatin and fenofibrate therapy
Arca, M., Natoli, S., Micheletta, F., Riggi, S., Angelantonio, E. D., Montali, A., Antonini, T., Antonini, R., Diczfalusy, U., & Iuliano, L. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.013 · Cited by 86
Active Metabolite of Atorvastatin Inhibits Membrane Cholesterol Domain Formation by an Antioxidant Mechanism
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513000200 · Cited by 86
Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women?
Wu, T., Willett, W. C., Rifai, N., Shai, I., Manson, J. E., & Rimm, E. B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.057 · Cited by 85
Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study
Mayr, M., Kiechl, S. J., Tsimikas, S., Miller, E. R., Sheldon, J., Willeit, J., Witztum, J. L., & Xu, Q. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.024 · Cited by 84
Self-citation
Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis
Hong, C. G., Florida, E. M., Li, H., Parel, P. M., Mehta, N. N., & Sorokin, A. V. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1023651 · Cited by 88
Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering
Tsimikas, S., Aikawa, M., Miller, F. J., Miller, E. R., Torzewski, M., Lentz, S. R., Bergmark, C., Heistad, D. D., Libby, P., & Witztum, J. L. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000251501.86410.03 · Cited by 82
Self-citation
Transient Increase in Plasma Oxidized LDL During the Progression of Atherosclerosis in Apolipoprotein E Knockout Mice
Kato, R., Mori, C., Kitazato, K. T., Arata, S., Obama, T., Mori, M., Takahashi, K., Aiuchi, T., Takano, T., & Itabe, H. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.164723 · Cited by 83
Reduction of oxidative stress and modulation of autoantibodies against modified low‐density lipoprotein after rosuvastatin therapy
Resch, U., Tatzber, F., Budinsky, A. C., & Sinzinger, H. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02568.x · Cited by 80
Comparison Effect of Atorvastatin (10 versus 80 mg) on Biomarkers of Inflammation and Oxidative Stress in Subjects With Metabolic Syndrome
Singh, U. S., Devaraj, S., Jialal, I., & Siegel, D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.057 · Cited by 80
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
Tada, H., Kawashiri, M., Yoshida, T., Teramoto, R., Nohara, A., Konno, T., Inazu, A., Mabuchi, H., Yamagishi, M., & Hayashi, K. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0999 · Cited by 79
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism
Mason, R. P., & Jacob, R. F. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.016 · Cited by 78
Clinical significance of the humoral immune response to modified LDL
Lopes-Virella, M. F., & Virella, G. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.04.001 · Cited by 76
Hyperlipidemia, tissue factor, coagulation, and simvastatin
Owens, A. P., Byrnes, J. R., & Mackman, N. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2013.07.003 · Cited by 78
Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization
Torzewski, M., Shaw, P. X., Han, K.-R., Shortal, B. P., Lackner, K. J., Witztum, J. L., Palinski, W., & Tsimikas, S. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000149378.98458.fe · Cited by 76
Self-citation
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy
Byun, Y. S., Lee, J., Arsenault, B. J., Yang, X., Bao, W., DeMicco, D. A., Laskey, R. E., Witztum, J. L., & Tsimikas, S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.050 · Cited by 76
Self-citation
The impact of age on 6-month survival in patients with cardiovascular risk factors undergoing elective non-cardiac surgery
Naughton, C., & Feneck, R. O. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01304.x · Cited by 75
Lipoprotein(a), platelet function and cardiovascular disease
Bhatia, H. S., Becker, R. C., Leibundgut, G., Patel, M. P., Lacaze, P. A., Tonkin, A. M., Narula, J., & Tsimikas, S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00947-2 · Cited by 82
Self-citation
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis
Moriarty, P. M., Gorby, L. K., Stroes, E. S. G., Kastelein, J. J. P., Davidson, M. H., & Tsimikas, S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00867-3 · Cited by 72
Self-citation
Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation
Dzobo, K. E., Cupido, A. J., Mol, B. M., Stiekema, L. C. A., Versloot, M., Winkelmeijer, M., Peter, J., Pennekamp, A.-M., Havik, S. R., Vaz, F. M., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319937 · Cited by 74
Self-citation
Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with Atorvastatin active metabolite compared with other triglyceride-lowering agents
Mason, R. P., Sherratt, S. C. R., & Jacob, R. F. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000379 · Cited by 72
In Vivo Markers of Oxidative Stress and Therapeutic Interventions
Tsimikas, S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.006 · Cited by 67
Self-citation
Biomarkers of Inflammation and Oxidative Stress in Atherosclerosis
Uno, K., & Nicholls, S. J. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.57 · Cited by 65
Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?
Ray, K. K., Cannon, C. P., & Ganz, P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.016 · Cited by 64
Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes
Younis, N. N., Soran, H., Pemberton, P. W., Charlton-Menys, V., Elseweidy, M. M., & Durrington, P. N. (2012) · Clinical Science · doi:10.1042/cs20120304 · Cited by 66
Atherogenesis and the humoral immune response to modified lipoproteins
Virella, G., & Lopes-Virella, M. F. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.025 · Cited by 63
Lipoprotein(a)
Tsimikas, S. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000237 · Cited by 64
Self-citation
Emerging therapeutic agents to lower lipoprotein (a) levels
Kolski, B. C., & Tsimikas, S. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283598d81 · Cited by 64
Self-citation
New and Emerging Risk Factors for Coronary Heart Disease
Akhabue, E., Thiboutot, J. P., Cheng, J.-W., Lerakis, S., Vittorio, T. J., Christodoulidis, G., Grady, K. M., & Kosmas, C. E. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828aab45 · Cited by 64
Lipoprotein a: where are we now?
Τζιόμαλος, Κ., Athyros, V. G., Wierzbicki, A. S., & Mikhailidis, D. P. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832ac21a · Cited by 56
Unique Antibody Responses to Malondialdehyde-Acetaldehyde (MAA)-Protein Adducts Predict Coronary Artery Disease
Anderson, D. R., Duryee, M. J., Shurmur, S. W., Um, J. Y., Bussey, W. D., Hunter, C. D., Garvin, R. P., Sayles, H. R., Mikuls, T. R., Klassen, L. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107440 · Cited by 56
Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype
Yahya, R., Berk, K. A., Verhoeven, A. J. M., Bos, S., van der Zee, L., Touw, J., Erhart, G., Kronenberg, F., Timman, R., Sijbrands, E. J. G., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.001 · Cited by 56
Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events
Prasad, A., Clopton, P., Ayers, C. R., Khera, A., de Lemos, J. A., Witztum, J. L., & Tsimikas, S. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309101 · Cited by 55
Self-citation
Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack
Byun, Y. S., Yang, X., Bao, W., DeMicco, D. A., Laskey, R. E., Witztum, J. L., & Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.057 · Cited by 54
Self-citation
Ongoing clinical trials of the pleiotropic effects of statins
Davignon, J., & Leiter, L. A. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.1.1.29.58937 · Cited by 51
Pathogenic Role of Modified LDL Antibodies and Immune Complexes in Atherosclerosis
Lopes-Virella, M. F., & Virella, G. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.19281 · Cited by 52
Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
Cai, A., Li, L., Zhang, Y., Mo, Y., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/563717 · Cited by 53
A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Cao, Y., Liu, H., Li, S., & Li, J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0303-2 · Cited by 51
Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration
Mendieta, G., Ben‐Aicha, S., Gutiérrez, M., Casaní, L., Aržanauskaitė, M., Carreras, F., Sabaté, M., Badimón, L., & Vilahur, G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.042 · Cited by 51
Inflammatory Biomarkers in Acute Coronary Syndromes
Armstrong, E. J., Morrow, D. A., & Sabatine, M. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595546 · Cited by 50

Authors: Tsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G.
Affiliations: Linköping University (SE)
Corresponding author: Tsimikas, Sotirios
ORCID: Tsimikas, Sotirios
Witztum, Joseph L.
Miller, Elizabeth R.
Sasiela, William J.
Szarek, Michael
Olsson, Anders G.
Schwartz, Gregory G.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-09-14
Volume: 110
Issue: 11
Pages: 1406-1412
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000141728.23033.b5
OpenAlex: W2109629533
Semantic Scholar: 5d8d1d7bcae3432d2e03d42643169af12f5e5419
Cited by: 225
References: 45
Citations by year: 2026: 2 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 15 · 2015: 13 · 2014: 10 · 2013: 10 · 2012: 9
FWCI: 14.84
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Donald W. Reynolds Foundation
Pfizer
National Heart, Lung, and Blood Institute (P50HL056989, HL-56989)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: atorvastatin, oxidized phospholipids, oxidized LDL, apolipoprotein B-100, immune complexes, lipoprotein(a), acute coronary syndrome, statin therapy, atherosclerosis, atherosclerotic plaque
MeSH terms: Atorvastatin, Aged, Angina, Unstable, Antigen-Antibody Complex, Apolipoproteins B, Autoantibodies, Double-Blind Method, Female, Heptanoic Acids, Humans, Immunoglobulin G, Immunoglobulin M, Lipoproteins, LDL, Male, Middle Aged, Myocardial Infarction, Oxidation-Reduction, Phospholipids, Pyrroles, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Apolipoprotein B-100

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks